Novo Holdings Portfolio Company Amolyt Pharma Enters into Definitive Agreement to be Acquired by AstraZeneca
Published on 08/07/2025 at 18:04 | prnewswire.co.uk
Deal value up to US$1.05 billionNovo Holdings co-led Series A financing in Amolyt, supported additional financings and is Amolyt's largest investor Acquisition validates Novo Holdings' strategy to identify and invest long term in high quality European biotech companiesView original content:https://www.prnewswire.co.uk/news-releases/novo-holdings-portfolio-company-amolyt-pharma-enters-into-definitive-agreement-to-be-acquired-by-astrazeneca-302089163.html
en | boerse | 67982045 |
